GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » EPS without NRI

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) EPS without NRI : $-0.75 (TTM As of Sep. 2018)


View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals EPS without NRI?

Keryx Biopharmaceuticals's earnings per share without non-recurring items for the three months ended in Sep. 2018 was $-0.14. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.75.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -6.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -40.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Keryx Biopharmaceuticals's EPS without NRI or its related term are showing as below:

KERX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0   Med: -18.1   Max: 43.3
Current: -6.6

During the past 13 years, Keryx Biopharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 43.30% per year. The lowest was 0.00% per year. And the median was -18.10% per year.

KERX's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.1 vs KERX: -6.60

Keryx Biopharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2018 was $-0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.75.

Keryx Biopharmaceuticals's EPS (Basic) for the three months ended in Sep. 2018 was $-0.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.75.


Keryx Biopharmaceuticals EPS without NRI Historical Data

The historical data trend for Keryx Biopharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals EPS without NRI Chart

Keryx Biopharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.58 -1.23 -1.19 -1.52 -1.43

Keryx Biopharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.25 -0.18 -0.18 -0.14

Competitive Comparison of Keryx Biopharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Keryx Biopharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keryx Biopharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's PE Ratio without NRI falls into.



Keryx Biopharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keryx Biopharmaceuticals  (NAS:KERX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Keryx Biopharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.
Executives
Scott A Holmes officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison director, officer: Interim CEO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma director, 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison director, officer: President and CEO ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams officer: General Counsel and Secretary 750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Headlines

From GuruFocus

Keryx Pharmaceuticals Announces Upcoming Investor Presentations

By Marketwired Marketwired 05-30-2018

Klarman Gives Insight on Keryx Biopharmaceuticals Investment

By Bram de Haas Bram de Haas 01-26-2016